Please assess the completion status of the following clinical trial:

Trial Title: Defibrotide TMA Prophylaxis Pilot Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Age 0-30 years of age~2. Life expectancy \> 6 months~3. Eastern Cooperative Oncology Group or Karnofsky Performance Status \>40~4. Meets minimum organ function requirements per institutional standard of care guiding clearance for autologous or allogeneic stem cell transplantation.~5. Patients must meet TMA High-Risk criteria 5A or 5B below:~5A. Patients undergoing tandem autologous transplant with thiotepa in one or more of the conditioning regimens~OR:~5B. . Patients with at least 3 of the following characteristics:~1. \>10 years of age~2. Non-Caucasian race/ Hispanic ethnicity~3. Undergoing haploidentical transplant~4. Minor ABO blood group mismatch~Exclusion Criteria:~1. Age \>30 years~2. Life expectancy \< 6 months~3. Known bleeding diathesis or bleeding risk deemed by the treating physician to be a contraindication to administration of anticoagulants.~4. Known hypersensitivity reaction to defibrotide~5. Any patient not meeting TMA High-Risk criteria~6. Pregnant women are excluded from this study because they will be receiving teratogenic therapy as part of the stem cell transplant.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Prophylactic Defibrotide (Type: EXPERIMENTAL): 6.25mg/kg administered intravenously every 6 hours for 28 to 35 days, starting on the day before conditioning is initiated.

Based on this trial design, predict the completion outcome and termination type (if applicable).